Skip to main content
SpringerLink
Log in

Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction

  • Chapter
  • First Online:
Heart Failure

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 243))

Abstract

Biomarkers are increaingly being used in the management of heart failure not only for the purpose of screening, diagnosis, and risk stratification, but also as a guide to evaluate the response to treatment in the individual patient and as an entry criterion and/or a surrogate marker of efficacy in clinical trials testing novel drugs. In this chapter, we review the role of established biomarkers for heart failure management, according to the main classification of HF phenotypes, based on the measurement of left ventricular ejection fraction, including heart failure with reduced (<40%), preserved (≥50%), and, as recently proposed, mid-range (40-49%) ejection fraction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH (2010) Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 16:49–54

    Article  CAS  PubMed  Google Scholar 

  • Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN (2003) Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283

    Article  CAS  PubMed  Google Scholar 

  • Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators (2005) C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112:1428–1434

    Article  CAS  PubMed  Google Scholar 

  • Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC (2010) Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122:1387–1395

    Article  CAS  PubMed  Google Scholar 

  • Anand IS, Rector TS, Cleland JG et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569–577

    Article  CAS  PubMed  Google Scholar 

  • Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN (2014) Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 7:418–426

    Article  CAS  PubMed  Google Scholar 

  • Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C, Pinto Y, Richards MA, Januzzi JL (2007) Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 381:145–150

    Article  CAS  PubMed  Google Scholar 

  • Berry C, Murphy NF, De Vito G, Galloway S, Seed A, Fisher C, Sattar N, Vallance P, Hillis WS, McMurray J (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 9:429–434

    Article  CAS  PubMed  Google Scholar 

  • Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47:338–341

    Article  CAS  PubMed  Google Scholar 

  • Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159

    Article  CAS  PubMed  Google Scholar 

  • Braunwald E (2013) Heart failure. J Am Coll Cardiol 1:1–20

    Article  Google Scholar 

  • Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van der Harst P, de Boer RA (2014) Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail 7:723–731

    Article  CAS  PubMed  Google Scholar 

  • Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlström U, Pinto YM, Karlström P, Erntell H, Berger R, Persson H, O’Connor CM, Moertl D, Gaggin HK, Frampton CM, Nicholls MG, Troughton RW (2015) Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail 17:1252–1261

    Article  CAS  PubMed  Google Scholar 

  • Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O’Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M (2014) Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2:97–112

    Article  PubMed  PubMed Central  Google Scholar 

  • Cabassi A, de Champlain J, Maggiore U, Parenti E, Coghi P, Vicini V, Tedeschi S, Cremaschi E, Binno S, Rocco R, Bonali S, Bianconcini M, Guerra C, Folesani G, Montanari A, Regolisti G, Fiaccadori E (2013) Prealbumin improves death risk prediction of BNP-added Seattle Heart Failure Model: results from a pilot study in elderly chronic heart failure patients. Int J Cardiol 168:3334–3339

    Article  PubMed  Google Scholar 

  • Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M, Pérez-Calvo JI (2013) Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 169:177–182

    Article  PubMed  Google Scholar 

  • Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong RC, Chai P, Low AF, Richards AM, Lam CS (2016) Growth differentiation factor 15 in heart failure with preserved vs reduced ejection fraction. Eur J Heart Fail 18:81–88

    Article  CAS  PubMed  Google Scholar 

  • Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140

    Article  CAS  PubMed  Google Scholar 

  • Clark H, Krum H, Hopper I (2014) Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail 16:41–48

    Article  CAS  PubMed  Google Scholar 

  • Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50:33–50

    Article  CAS  PubMed  Google Scholar 

  • Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications (2006) Am J Physiol Heart Circ Physiol 290:H17–29

    Google Scholar 

  • Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A (2009) Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 53:2343–2348

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823

    Article  CAS  PubMed  Google Scholar 

  • Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R (2011) Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 32:2705–2712

    Article  CAS  PubMed  Google Scholar 

  • Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL (2012) Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 98:319–324

    Article  CAS  PubMed  Google Scholar 

  • Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW (2006) Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113:977–985

    Article  CAS  PubMed  Google Scholar 

  • de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28:89–94

    Google Scholar 

  • de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11:811–817

    Article  PubMed  CAS  Google Scholar 

  • de Boer RA, Lok DJ, Jaarsma T et al (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68

    Article  PubMed  CAS  Google Scholar 

  • Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T (2009a) Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta 400:91–96

    Article  CAS  PubMed  Google Scholar 

  • Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T (2009b) Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta 409:33–40

    Article  CAS  PubMed  Google Scholar 

  • Don-Wauchope AC, McKelvie RS (2015) Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem 48:236–246

    Article  CAS  PubMed  Google Scholar 

  • Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681–689

    Article  CAS  PubMed  Google Scholar 

  • Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791

    Article  CAS  PubMed  Google Scholar 

  • Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223

    Article  CAS  PubMed  Google Scholar 

  • Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, Zucchelli GC, Clerico A (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42:627–636

    Article  CAS  PubMed  Google Scholar 

  • Emdin M, Vittorini S, Passino C, Clerico A (2009) Old and new biomarkers of heart failure. Eur J Heart Fail 11:331–335

    Article  CAS  PubMed  Google Scholar 

  • Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G, Kremastinos DT (2010) Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol 139:75–79

    Article  PubMed  Google Scholar 

  • Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158:422–430

    Article  CAS  PubMed  Google Scholar 

  • Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O’Connor CM (2012) Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 5:72–78

    Article  CAS  PubMed  Google Scholar 

  • Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, Greenberg BH, Filippatos G, Davison BA, Cotter G, Prescott MF, Hua TA, Lopez-Pintado S, Severin T, Metra M (2015) Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail 17:1262–1270

    Article  CAS  PubMed  Google Scholar 

  • Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:1943–1950

    Article  CAS  PubMed  Google Scholar 

  • Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert JC, Cleland JG (2007) Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28:1592–1597

    Article  CAS  PubMed  Google Scholar 

  • Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832:2442–2450

    Article  CAS  PubMed  Google Scholar 

  • Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, Wang TJ, Januzzi JL Jr (2014) Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2:65–72

    Article  PubMed  Google Scholar 

  • Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Brunner-La Rocca HP, Januzzi JL Jr (2015) Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J 169:404–411

    Article  CAS  PubMed  Google Scholar 

  • Gerdes AM, Iervasi G (2010) Thyroid replacement therapy and heart failure. Circulation 122:385–393

    Article  PubMed  Google Scholar 

  • Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385–1390

    Article  CAS  PubMed  Google Scholar 

  • Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(89–95)

    Google Scholar 

  • Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754–1761

    Article  PubMed  CAS  Google Scholar 

  • Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P, on behalf of the CORONA Study Group (2012) Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 33:2290–2296

    Article  CAS  PubMed  Google Scholar 

  • Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230:160–171

    Article  CAS  PubMed  Google Scholar 

  • Hillege HL, Girbes AR, de Kam PJ, Boomsma F, De ZD, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210

    Article  CAS  PubMed  Google Scholar 

  • Horwich TB, Patel J, MacLellan WR, Fonarow GC (2003) Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108:833–838

    Article  CAS  PubMed  Google Scholar 

  • Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A, Preiss D, Anker SD, Sattar N, Petrie MC, Gardner RS, McMurray JJ (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail [Epub ahead of print]

    Google Scholar 

  • Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M (2006a) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330–337

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL Jr, Sakhuja R, O’donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA Jr, Lloyd-Jones DM (2006b) Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166:315–320

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50:607–613

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL Jr, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM (2010) Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin Chem 56:1814–1821

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58:1881–1889

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL Jr, Maisel AS, Silver M, Xue Y, DeFilippi C (2012) Natriuretic peptide testing for predicting adverse events following heart failure hospitalization. Congest Heart Fail 18(Suppl 1):S9–S13

    Article  CAS  PubMed  Google Scholar 

  • Januzzi JL, Pascual-Figal D, Daniels LB (2015) ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol 115(7 Suppl):70B–75B

    Article  PubMed  Google Scholar 

  • Jhund PS, Anand IS, Komajda M et al (2015) Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail 17:809–817

    Article  CAS  PubMed  Google Scholar 

  • Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739

    Article  CAS  PubMed  Google Scholar 

  • Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C, Endemann D, Banas B, Mack M, Boger CA, Riegger G, Luchner A (2011) Kidney injury molecule-1 and N-acetyl-beta-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 13:1104–1110

    Article  CAS  PubMed  Google Scholar 

  • Kakkar R, Lee RT (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7:827–840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim HN, Januzzi JL Jr (2010) Biomarkers in the management of heart failure. Curr Treat Options Cardiovasc Med 12:519–531

    Article  PubMed  Google Scholar 

  • Kleber ME, Koller L, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer TB, Delgado G, Tomaschitz A, Pilz S, März W, Von NA (2015) Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail 8:25–32

    Article  CAS  PubMed  Google Scholar 

  • Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 4:628–636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kühl U, Noutsias M, Seeberg B, Schultheiss HP (1996) Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 75:295–300

    Article  PubMed  PubMed Central  Google Scholar 

  • Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55:53–60

    Article  PubMed  CAS  Google Scholar 

  • Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106:2454–2458

    Article  CAS  PubMed  Google Scholar 

  • Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249

    Article  CAS  PubMed  Google Scholar 

  • Lee AF, MacFadyen RJ, Struthers AD (1999) Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1:401–406

    Article  CAS  PubMed  Google Scholar 

  • Leimbach WN, Wallin BG, Victor RG, Alyward PE, Sundlof G, Mark AL (1986) Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913–919

    Article  PubMed  Google Scholar 

  • Lim PO, MacFadyen RJ, Struthers AD (2000) Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment? Heart 83:257–261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99

    Article  CAS  PubMed  Google Scholar 

  • Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010) HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 16:e1–e194

    Article  PubMed  Google Scholar 

  • Lippi G, Sanchis-Gomar F (2016) Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge? Int J Cardiol 219:111–114

    Article  PubMed  Google Scholar 

  • Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323–328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, van der Weide P, Klöpping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA (2012) Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 14:1249–1256

    Article  CAS  PubMed  Google Scholar 

  • Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P (2012) Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14:74–81

    Article  PubMed  CAS  Google Scholar 

  • Lourenço P, Paulo Araújo J, Paulo C, Mascarenhas J, Friões F, Azevedo A, Bettencourt P (2010) Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients. Clin Cardiol 33:708–714

    Article  PubMed  Google Scholar 

  • Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP, TIME-CHF Investigators (2013) N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 15:1148–1156

    Article  CAS  PubMed  Google Scholar 

  • Maisel AS, Krishnaswamy P, Nowak RM, et al., Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167

    Google Scholar 

  • Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD (2011a) Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 58:1057–1067

    Article  CAS  PubMed  Google Scholar 

  • Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ (2011b) Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 13:846–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand IS, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD (2011c) Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 4:613–620

    Article  CAS  PubMed  Google Scholar 

  • Mann DL (2015) Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116:1254–1268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602

    Article  CAS  PubMed  Google Scholar 

  • Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL (2011) Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107:259–267

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, Val-HeFT Investigators (2006) Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52:1528–1538

    Article  CAS  PubMed  Google Scholar 

  • Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN, Val-HeFT Investigators (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003

    Article  CAS  PubMed  Google Scholar 

  • Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L, GISSI-HF Investigators (2010a) The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 12:338–347

    Article  CAS  PubMed  Google Scholar 

  • Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, Frisinghelli A, Minneci C, Valisi M, Maggioni AP, Marchioli R, Tognoni G, Tavazzi L, GISSI-HF Investigators (2010b) Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. Circ Heart Fail 3:65–72

    Article  CAS  PubMed  Google Scholar 

  • Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R, Valsartan Heart Failure Trial (Val-HeFT), Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca–Heart Failure (GISSI-HF) Investigators (2012) Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125:280–288

    Article  CAS  PubMed  Google Scholar 

  • McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, Breathing Not Properly Multinational Study Investigators (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 41:571–579

    Article  CAS  PubMed  Google Scholar 

  • McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY (2008) Assessing new biomarkers and predictive models for use in clinical practice: a clinician’s guide. Arch Intern Med 168:2304–2310

    Article  PubMed  Google Scholar 

  • McKelvie RS, Komajda M, McMurray J et al (2010) Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 16:128–134

    Article  CAS  PubMed  Google Scholar 

  • McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120:2188–2196

    Article  CAS  PubMed  Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    Article  PubMed  CAS  Google Scholar 

  • Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R (2009) Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53:1783–1790

    Article  CAS  PubMed  Google Scholar 

  • Motiwala SR, Januzzi JL (2013) The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharmacol Ther 93:57–67

    Article  CAS  PubMed  Google Scholar 

  • Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A (2012) The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. J Intern Med 271:436–443

    Article  CAS  PubMed  Google Scholar 

  • Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54–61

    Article  CAS  PubMed  Google Scholar 

  • Palazzuoli A, Pellegrini M, Ruocco G, Martini G, Franci B, Campagna MS, Gilleman M, Nuti R, McCullough PA, Ronco C (2014) Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care 18:R134

    Article  PubMed  PubMed Central  Google Scholar 

  • Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, Schultheiss HP, Siems WE, Walther T (2007) Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 101:875–882

    Article  CAS  PubMed  Google Scholar 

  • Parekh N, Maisel AS (2009) Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 24:155–160

    Article  PubMed  Google Scholar 

  • Parikh NI, Vasan RS (2007) Assessing the clinical utility of biomarkers in medicine. Biomark Med 1:419–436

    Article  CAS  PubMed  Google Scholar 

  • Pascual-Figal DA, Januzzi JL (2015) The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 115:3B–7B

    Article  CAS  PubMed  Google Scholar 

  • Passino C, Severino S, Poletti R, Piepoli MF, Mammini C, Clerico A, Gabutti A, Nassi G, Emdin M (2006) Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 47:1835–1839

    Article  CAS  PubMed  Google Scholar 

  • Passino C, Poletti R, Fontana M, Vergaro G, Prontera C, Gabutti A, Giannoni A, Emdin M, Clerico A (2008) Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med 46:1515–1523

    Article  CAS  PubMed  Google Scholar 

  • Passino C, Pingitore A, Landi P, Fontana M, Zyw L, Clerico A, Emdin M, Iervasi G (2009) Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail 15:35–40

    Article  CAS  PubMed  Google Scholar 

  • Paulus WJ (2000) Cytokines and heart failure. Heart Fail Monit 1:50–56

    CAS  PubMed  Google Scholar 

  • Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH, ADHERE Investigators (2008) Cardiac troponin and outcome in acute heart failure. N Engl J Med 358:2117–2126

    Article  CAS  PubMed  Google Scholar 

  • Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172

    Article  PubMed  Google Scholar 

  • Pencina MJ, D’Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703–1711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301:383–392

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392

    Article  CAS  PubMed  Google Scholar 

  • Poletti R, Vergaro G, Zyw L, Prontera C, Passino C, Emdin M (2013) Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. Int J Cardiol 167:711–715

    Article  PubMed  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975

    Article  PubMed  Google Scholar 

  • Pozsonyi Z, Förhécz Z, Gombos T, Karádi I, Jánoskuti L, Prohászka Z (2015) Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. Heart Lung Circ 24:359–367

    Article  PubMed  Google Scholar 

  • Pruett AE, Lee AK, Patterson JH, Schwartz TA, Glotzer JM, Adams KF Jr (2015) Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. Curr Cardiol Rev 11:80–89

    Article  PubMed  PubMed Central  Google Scholar 

  • Putko BN, Yogasundaram H, Oudit GY (2014a) The harbinger of mortality in heart failure with preserved ejection fraction: do GDF-15 levels reflect tandem, deterministic effects of fibrosis and inflammation? Can J Cardiol 30:264–266

    Article  PubMed  Google Scholar 

  • Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, Kassiri Z, Oudit GY, Alberta HEART Investigators (2014b) Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One 9, e99495

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Qian C, Wei B, Ding J, Wu H, Wang Y (2016) The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Can J Cardiol 32:151–159

    Article  PubMed  Google Scholar 

  • Qiang L, Hong L, Ningfu W, Huaihong C, Jing W (2013) Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol 168:2082–2088

    Article  PubMed  Google Scholar 

  • Rehman SU, Mueller T, Januzzi JL Jr (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52:1458–1465

    Article  CAS  PubMed  Google Scholar 

  • Richards AM (2008) Serial measurements of plasma B-type natriuretic peptides: what do they tell us? J Am Coll Cardiol 52:1004–1005

    Article  PubMed  Google Scholar 

  • Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG, Australia-New Zealand Heart Failure Group (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37:1781–1787

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR (2008) Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther 22:305–311

    Article  CAS  PubMed  Google Scholar 

  • Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, GISSI-HF Investigators (2010) Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail 12:549–556

    Article  PubMed  CAS  Google Scholar 

  • Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM, Belgian RALES Investigators (2002) Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 40:1596–1601

    Article  CAS  PubMed  Google Scholar 

  • Sanada S et al (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117:1538–1549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators (2015) Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs reduced left ventricular ejection fraction. Eur J Heart Fail 17:1006–1014

    Article  CAS  PubMed  Google Scholar 

  • Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS (2012) Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs reduced ejection fraction. Eur J Heart Fail 14:1338–1347

    Article  CAS  PubMed  Google Scholar 

  • Semenov AG, Katrukha AG (2016) Different susceptibility of B-type natriuretic peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: the N-terminal part does matter. Clin Chem 62:617–622

    Article  CAS  PubMed  Google Scholar 

  • Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L, IN HF Outcome Investigators (2014) In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 173:163–169

    Article  PubMed  Google Scholar 

  • Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL (2009) Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2:311–319

    Article  CAS  PubMed  Google Scholar 

  • Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL (2010) Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12:826–832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, Li SY, de Filippi CR (2011) Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 57:874–882

    Article  CAS  PubMed  Google Scholar 

  • Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr (2012) Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33:2197–2205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332–337

    Article  CAS  PubMed  Google Scholar 

  • Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387–1395

    Article  CAS  PubMed  Google Scholar 

  • Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R (2010) The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12:1309–1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM (2010) MiR423-5p as a circulating biomarker for heart failure. Circ Res 106:1035–1039

    Article  CAS  PubMed  Google Scholar 

  • Tota B, Angelone T, Cerra MC (2014) The surging role of Chromogranin A in cardiovascular homeostasis. Front Chem 2:64

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Troughton RW, Frampton CM, Yandle TG et al (2000) Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130

    Article  CAS  PubMed  Google Scholar 

  • Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP (2005) The role of NT- proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26:2277–2284

    Article  PubMed  CAS  Google Scholar 

  • Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28:1723–1730

    Article  PubMed  Google Scholar 

  • van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–1224

    Article  PubMed  CAS  Google Scholar 

  • van Kimmenade RR, Pinto YM, Januzzi JL Jr (2008) Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol 101:39–42

    Article  PubMed  CAS  Google Scholar 

  • van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL (2013) B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61:1498–1506

    Article  PubMed  CAS  Google Scholar 

  • van Veldhuisen DJ, Ruilope LM, Maisel AS, Damman K (2015) Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. Eur Heart J pii: ehv588 [Epub ahead of print]

    Google Scholar 

  • Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpé S (2009) Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 47:248–252

    Article  CAS  PubMed  Google Scholar 

  • Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113:2335–2362

    Article  PubMed  Google Scholar 

  • Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA (2016) MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 18:457–468

    Article  CAS  PubMed  Google Scholar 

  • Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, Mammini C, Giannoni A, Fontana M, Passino C (2011) Prognostic value of plasma renin activity in heart failure. Am J Cardiol 108:246–251

    Article  CAS  PubMed  Google Scholar 

  • Vergaro G, Prud’homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A, Delcayre C (2016) Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension 67:606–612

    CAS  PubMed  Google Scholar 

  • Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N (2003) Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42:1793–1800

    Article  CAS  PubMed  Google Scholar 

  • Xue Y, Clopton P, Peacock WF, Maisel AS (2011) Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 13:37–42

    Article  CAS  PubMed  Google Scholar 

  • Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (2009) Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 73:1067–1073

    Article  CAS  PubMed  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(e147–239)

    Google Scholar 

  • Yu CM, Cheung BM, Leung R, Wang Q, Lai WH, Lau CP (2001) Increase in plasma adrenomedullin in patients with heart failure characterized by diastolic dysfunction. Heart 86:155–160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

    Michele Senni

  2. CardioVascular Department, Ospedale Papa Giovanni XXIII Hospital, Bergamo, Italy

    Michele Senni & Emilia D’Elia

  3. Life Science Institute, Scuola Superiore Sant’Anna, Pisa, Italy

    Michele Emdin & Giuseppe Vergaro

  4. Fondazione Toscana G. Monasterio, Pisa, Italy

    Michele Emdin & Giuseppe Vergaro

Authors
  1. Michele Senni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilia D’Elia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Emdin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Vergaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Senni .

Editor information

Editors and Affiliations

  1. Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover Klinik für Kardiologie und Angiologie, Hannover, Niedersachsen, Germany

    Johann Bauersachs

  2. Heart Institute, Stony Brook University , Stony Brook, New York, USA

    Javed Butler

  3. Heart and Lung Diseases, Bayer Pharma Aktiengesellschaft Heart and Lung Diseases, Wuppertal, Nordrhein-Westfalen, Germany

    Peter Sandner

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Senni, M., D’Elia, E., Emdin, M., Vergaro, G. (2016). Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. In: Bauersachs, J., Butler, J., Sandner, P. (eds) Heart Failure. Handbook of Experimental Pharmacology, vol 243. Springer, Cham. https://doi.org/10.1007/164_2016_86

Download citation

Publish with us

Policies and ethics

Search

Navigation